Patents by Inventor Françoise PIGUET

Françoise PIGUET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230279422
    Abstract: The use of recombinant AAV vectors expressing a molecule of interest in a method for treating diseases or conditions affecting the nervous system in a subject in need thereof, or in a method for increasing or inducing expression of the molecule of interest in the nervous system of a subject.
    Type: Application
    Filed: May 20, 2022
    Publication date: September 7, 2023
    Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITE
    Inventors: Françoise PIGUET, Caroline SEVIN
  • Publication number: 20220233654
    Abstract: Rett syndrome (RTT) is a neurodevelopmental disorder that affects girls almost exclusively (about 1 in 10 000 females). It is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability. Herein, the inventors demonstrated that delivering a vector expressing a cholesterol 24-hydroxylase (CYP46A1) gene intravenously in a mouse model of RTT is able to prevent/correct the development of motor impairment, in a mild and an aggravated model of the disease both in male and female mice. In addition in males, the inventors demonstrated a prevention of the loss of Purkinje cells and an improvement of astrogliosis and microgliosis in the mild KO MECP2 model.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 28, 2022
    Inventors: Françoise PIGUET, Nathalie CARTIER-LACAVE
  • Publication number: 20220054597
    Abstract: The present invention relates to a vector for use in the treatment of amyotrophic lateral sclerosis associated, or not associated, with fronto temporal dementia and related motoneuron disorders, which vector comprises cholesterol 24-hydroxylase encoding nucleic acid.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 24, 2022
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Françoise PIGUET, Nathalie CARTIER-LACAVE
  • Patent number: 11040113
    Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: June 22, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg
    Inventors: Hélène Puccio, Françoise Piguet
  • Publication number: 20180050117
    Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 22, 2018
    Inventors: Hélène PUCCIO, Françoise PIGUET